Advertisement
Research Article

Phase I Trial of an Alhydrogel Adjuvanted Hepatitis B Core Virus-Like Particle Containing Epitopes of Plasmodium falciparum Circumsporozoite Protein

  • Aric L. Gregson,

    Affiliation: Department of Medicine and Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America

    Current address: Division of Infectious Diseases, Department of Medicine, University of California Los Angeles, Los Angeles, California, United States of America,

    X
  • Giane Oliveira,

    Affiliation: Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, United States of America

    Current address: Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States of America

    X
  • Caroline Othoro,

    Affiliation: Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, United States of America

    X
  • J. Mauricio Calvo-Calle,

    Affiliation: Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, United States of America

    Current address: Department of Pathology, University of Massachusetts School of Medicine, Worcester, Massachusetts, United States of America

    X
  • George B. Thorton,

    Affiliation: Apovia, Inc., San Diego, California, United States of America

    X
  • Elizabeth Nardin,

    Affiliation: Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, United States of America

    X
  • Robert Edelman mail

    *E-mail: redelman@medicine.umaryland.edu.

    Affiliation: Department of Medicine and Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America

    X
  • Published: February 06, 2008
  • DOI: 10.1371/journal.pone.0001556

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.